273 related articles for article (PubMed ID: 31076371)
1. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2018.
Terpos E; Ntanasis-Stathopoulos I;
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e324-e336. PubMed ID: 31076371
[TBL] [Abstract][Full Text] [Related]
2. Clinical Updates Regarding Multiple Myeloma From the 2019 American Society of Hematology Annual Meeting.
Terpos E; Ntanasis-Stathopoulos I;
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):499-508. PubMed ID: 32376237
[TBL] [Abstract][Full Text] [Related]
3. Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma.
Marneni N; Chakraborty R
Curr Hematol Malig Rep; 2021 Apr; 16(2):148-161. PubMed ID: 33876390
[TBL] [Abstract][Full Text] [Related]
4. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting, 2017.
Terpos E;
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):321-334. PubMed ID: 29576386
[TBL] [Abstract][Full Text] [Related]
5. Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.
Offidani M; Corvatta L; Morè S; Nappi D; Martinelli G; Olivieri A; Cerchione C
Front Oncol; 2020; 10():624661. PubMed ID: 33680948
[TBL] [Abstract][Full Text] [Related]
6. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
[TBL] [Abstract][Full Text] [Related]
7. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2016.
Terpos E;
Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):329-339. PubMed ID: 28462890
[TBL] [Abstract][Full Text] [Related]
8. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
[TBL] [Abstract][Full Text] [Related]
9. Highlights of Multiple Myeloma at the Annual Meeting of American Society of Hematology, 2016.
Tandon N; Kumar SK
Indian J Hematol Blood Transfus; 2017 Jun; 33(2):153-158. PubMed ID: 28596644
[TBL] [Abstract][Full Text] [Related]
10. Isatuximab, carfilzomib and dexamethasone (Isa-Kd) for the management of relapsed multiple myeloma.
Banerjee R; Lo M; Martin TG
Future Oncol; 2021 Dec; 17(35):4849-4860. PubMed ID: 34553603
[TBL] [Abstract][Full Text] [Related]
11. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
[TBL] [Abstract][Full Text] [Related]
12. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone
Mateos MV; Masszi T; Grzasko N; Hansson M; Sandhu I; Pour L; Viterbo L; Jackson SR; Stoppa AM; Gimsing P; Hamadani M; Borsaru G; Berg D; Lin J; Di Bacco A; van de Velde H; Richardson PG; Moreau P
Haematologica; 2017 Oct; 102(10):1767-1775. PubMed ID: 28751562
[TBL] [Abstract][Full Text] [Related]
13. Are maintenance and continuous therapies indicated for every patient with multiple myeloma?
Musto P; Montefusco V
Expert Rev Hematol; 2016 Aug; 9(8):743-51. PubMed ID: 27268855
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
[TBL] [Abstract][Full Text] [Related]
15. Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
Xu W; Sun X; Wang B; Guo H
Ann Hematol; 2018 Feb; 97(2):299-307. PubMed ID: 29159498
[TBL] [Abstract][Full Text] [Related]
16. Progress in the Management of Smoldering Multiple Myeloma.
Schmidt TM; Callander NS
Curr Hematol Malig Rep; 2021 Apr; 16(2):172-182. PubMed ID: 33983517
[TBL] [Abstract][Full Text] [Related]
17. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
[TBL] [Abstract][Full Text] [Related]
18. Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting.
Garderet L; Cook G; Auner HW; Bruno B; Lokhorst H; Perez-Simon JA; Sahebi F; Scheid C; Morris C; van Biezen A; Sobh M; Michallet M; Gahrton G; Schönland S; Kröger N
Leuk Lymphoma; 2017 Apr; 58(4):797-808. PubMed ID: 27650125
[TBL] [Abstract][Full Text] [Related]
19. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma.
Dimopoulos MA; Jakubowiak AJ; McCarthy PL; Orlowski RZ; Attal M; Bladé J; Goldschmidt H; Weisel KC; Ramasamy K; Zweegman S; Spencer A; Huang JSY; Lu J; Sunami K; Iida S; Chng WJ; Holstein SA; Rocci A; Skacel T; Labotka R; Palumbo A; Anderson KC
Blood Cancer J; 2020 Feb; 10(2):17. PubMed ID: 32054831
[TBL] [Abstract][Full Text] [Related]
20. Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020.
Du J; Zhuang J
Chronic Dis Transl Med; 2021 Dec; 7(4):220-226. PubMed ID: 34786541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
